•    

All fields are required.

Close Appointment form

Board of Directors

Improving patient outcomes with innovative drug therapies.

Benjamin Wolin

Board Chairman

Benjamin Wolin has served as a Director and Chairman of our Board since March 2018.

Mr. Wolin is also the Lead Independent Director of Diplomat Pharmacy (DPLO), Director of Covetrus (CVET) and serves as an advisor to 3L Capital.

From 2002 to 2016, Mr. Wolin was the Co-founder, Chief Executive Officer and a Member of the Board of Directors of Everyday Health (EVDY), a leading provider of digital health and wellness solutions, until its sale to a subsidiary of j2 Global (JCOM).

Mr. Wolin received his B.A. from Bowdoin College.

John Cooper

Director

John Cooper has served as a Director on our Board and Chair of the Audit Committee since September 2017.

Mr. Cooper’s career spans over 30 years of senior executive experience managing publicly-traded companies in the life sciences industry. He has played key leadership roles building companies with transformational medical technologies, including the first FDA approved synthetic peptide-containing pulmonary surfactant for premature infants with severe respiratory disease and the second FDA approved blood diagnostic test for HIV. Mr. Cooper has significant experience in corporate and organization development, raising capital, mergers and acquisitions, strategic alliances, investor relations, and corporate governance. Over his career, Mr. Cooper has raised approximately $1 billion in capital through various financing and strategic transactions. Currently, Mr. Cooper provides corporate development and financial advisory services to emerging public and private companies in the life sciences industry.

Mr. Cooper held executive leadership positions for Windtree Therapeutics (formerly Discovery Laboratories), a specialty biopharmaceutical company focused on respiratory therapeutics, from 2001 to 2016. His roles included President, Chief Executive Officer and Member of the Board of Directors, President and Chief Financial Officer, Executive Vice President and Chief Financial Officer. Prior to Discovery Labs, Mr. Cooper served as Senior Vice President and Chief Financial Officer at Chrysalis International Corporation (acquired by Phoenix Life Sciences) and its predecessor DNX Corporation, where he managed its initial public offering and negotiated and integrated several strategic acquisitions. Previously, Mr. Cooper served in senior financial management and executive committee roles at ENI Diagnostics (acquired by Pharmacia AB).

Mr. Cooper received his B.S. in Commerce from Rider University and holds a CPA designation.

Robin Smith, M.D.

Director

Robin Smith, M.D., has served as a Director on our Board since June 2016.

Dr. Smith currently serves as a Board Member for NeoStem and Wellfleet Partners. During her tenure as Chief Executive Officer of the NeoStem family of companies, she pioneered the company’s innovative business model, combining proprietary cell therapy development with a successful contract development and manufacturing organization. Dr. Smith raised over $200 million, completing six acquisitions and one divestiture while the company won an array of industry awards and business recognition, including a first-place ranking in the tri-state area (two years in a row), and eleventh place nationally, on Deloitte’s Technology Fast 500, and Frost & Sullivan’s North American Cell Therapeutics Technology Innovation Leadership Award.

In 2008, Dr. Smith founded the Stem for Life Foundation (SFLF), a nonpartisan 501(c)3 educational organization devoted to fostering global regenerative medicine awareness. From 1999 to 2001, Dr. Smith was also an Adjunct Assistant Professor in Radiology at Thomas Jefferson University.

Dr. Smith received her MBA from the Wharton School of the University of Pennsylvania and her M.D. from Yale School of Medicine.

Mark Ravich

Director

Mark Ravich has served as a Director on our Board since June 2017.

Mr. Ravich is the President of Tri-Star Management, which he co-founded in 1998. Additionally, he serves as the chief manager of various real estate entities. He is also a Director of Dilion Technologies and Orchids Paper Products Company, where he serves as Chairman of its Governance Committee and a Member of its Audit Committee. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the Chief Executive Officer and a Director of Universal International.

Mr. Ravich received his BSE and MBA, Magna Cum Laude, from the Wharton School of the University of Pennsylvania.

Lisa Colleran

Director

Lisa Colleran has served as a Director on our Board since March 2018.

Ms. Colleran is the Principal of LNC Advisors, a strategic consulting firm that specializes in assisting biotech, pharmaceutical and medical device companies. She also currently serves on the Board of Directors for Establishment Labs and Ariste Medical.

Prior to founding LNC Advisors, Ms. Colleran served as Chief Executive Officer of LifeCell Corporation and a Board Member for Centaur Guerney, the holding company for LifeCell Corporation. From 2013 to 2018, Ms. Colleran also served as the Global President of LifeCell Corporation. Prior to assuming the role of Global President, Ms. Colleran served in numerous other roles at LifeCell, enhancing her expertise in marketing, business development and commercial operations. Before joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare in the Renal Division and her last position there was Vice President and General Manager of Renal Pharmaceuticals.

Ms. Colleran received her BSN from Molloy College and her MBA from Loyola University of Chicago.